Want to see INSM full AI Analyst Report?

Insmed (INSM) Stock Forecast & Price Target

1,281 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSM Analyst Ratings

Strong Buy

19 Buy

0 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$201.06

▲(88.04% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $201.06 with a high forecast of $243.00 and a low forecast of $169.00. The average price target represents a 88.04% change from the last price of $106.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"97":"$97","244":"$244","133.75":"$133.8","170.5":"$170.5","207.25":"$207.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$243.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":201.05555555555554,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$201.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$169.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[97,133.75,170.5,207.25,244],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.6,109.7076923076923,120.8153846153846,131.9230769230769,143.03076923076924,154.1384615384615,165.24615384615385,176.35384615384615,187.46153846153845,198.56923076923076,209.67692307692306,220.7846153846154,231.8923076923077,{"y":243,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.6,106.48119658119657,114.36239316239316,122.24358974358974,130.12478632478633,138.0059829059829,145.88717948717948,153.76837606837606,161.64957264957263,169.53076923076924,177.41196581196579,185.2931623931624,193.17435897435897,{"y":201.05555555555554,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.6,104.0153846153846,109.43076923076923,114.84615384615384,120.26153846153846,125.67692307692307,131.09230769230768,136.5076923076923,141.9230769230769,147.33846153846153,152.75384615384615,158.16923076923075,163.58461538461538,{"y":169,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$243.00

Average Price Target$201.06

Lowest Price Target$169.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$220

Buy

105.76%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)

Danielle Brill

Truist Financial

$185→$195

Buy

82.38%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

$179→$175

Buy

63.67%

Upside

Assigned

08/10/26

Insmed price target lowered to $175 from $179 at JPMorganInsmed price target lowered to $175 from $179 at JPMorgan

Gavin Clark-Gartner

Evercore ISI

$160→$170

Buy

59.00%

Upside

Reiterated

08/07/26

Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI

Jason Zemansky

Bank of America Securities

$212→$214

Buy

100.15%

Upside

Reiterated

08/07/26

Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)

Ashwani Verma

UBS

$166→$172

Buy

60.87%

Upside

Reiterated

08/07/26

Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS

Eliana Merle

Barclays

$237

Buy

121.66%

Upside

Reiterated

08/07/26

Barclays Reaffirms Their Buy Rating on Insmed (INSM)

Adam Walsh

Roth MKM

$212

Buy

98.28%

Upside

Reiterated

08/07/26

Roth MKM Reaffirms Their Buy Rating on Insmed (INSM)

Ritu Baral

TD Cowen

$243

Buy

127.27%

Upside

Reiterated

08/06/26

Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating

Faisal Khurshid

Jefferies

$160→$175

Buy

63.67%

Upside

Reiterated

08/06/26

Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies

Leonid Timashev

RBC Capital

$195

Buy

82.38%

Upside

Reiterated

08/06/26

RBC Capital Sticks to Their Buy Rating for Insmed (INSM)

Vamil Divan

Guggenheim

$207→$205

Buy

91.73%

Upside

Reiterated

08/06/26

Insmed price target lowered to $205 from $207 at GuggenheimInsmed price target lowered to $205 from $207 at Guggenheim

Maxwell Skor

Morgan Stanley

$212→$218

Buy

103.89%

Upside

Assigned

08/06/26

Morgan Stanley Sticks to Its Buy Rating for Insmed (INSM)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/06/26

Matt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story

Benjamin Burnett

Wells Fargo

$161→$169

Buy

58.06%

Upside

Assigned

08/06/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Qiagen (NYSE: QGEN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$220

Buy

105.76%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)

Danielle Brill

Truist Financial

$185→$195

Buy

82.38%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

$179→$175

Buy

63.67%

Upside

Assigned

08/10/26

Insmed price target lowered to $175 from $179 at JPMorganInsmed price target lowered to $175 from $179 at JPMorgan

Gavin Clark-Gartner

Evercore ISI

$160→$170

Buy

59.00%

Upside

Reiterated

08/07/26

Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI

Jason Zemansky

Bank of America Securities

$212→$214

Buy

100.15%

Upside

Reiterated

08/07/26

Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)

Ashwani Verma

UBS

$166→$172

Buy

60.87%

Upside

Reiterated

08/07/26

Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS

Eliana Merle

Barclays

$237

Buy

121.66%

Upside

Reiterated

08/07/26

Barclays Reaffirms Their Buy Rating on Insmed (INSM)

Adam Walsh

Roth MKM

$212

Buy

98.28%

Upside

Reiterated

08/07/26

Roth MKM Reaffirms Their Buy Rating on Insmed (INSM)

Ritu Baral

TD Cowen

$243

Buy

127.27%

Upside

Reiterated

08/06/26

Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating

Faisal Khurshid

Jefferies

$160→$175

Buy

63.67%

Upside

Reiterated

08/06/26

Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies

Leonid Timashev

RBC Capital

$195

Buy

82.38%

Upside

Reiterated

08/06/26

RBC Capital Sticks to Their Buy Rating for Insmed (INSM)

Vamil Divan

Guggenheim

$207→$205

Buy

91.73%

Upside

Reiterated

08/06/26

Insmed price target lowered to $205 from $207 at GuggenheimInsmed price target lowered to $205 from $207 at Guggenheim

Maxwell Skor

Morgan Stanley

$212→$218

Buy

103.89%

Upside

Assigned

08/06/26

Morgan Stanley Sticks to Its Buy Rating for Insmed (INSM)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/06/26

Matt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story

Benjamin Burnett

Wells Fargo

$161→$169

Buy

58.06%

Upside

Assigned

08/06/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Qiagen (NYSE: QGEN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months

Jessica FyeJ.P. Morgan

Success Rate

16/21 ratings generated profit

Average Return

+25.57%

Copying Jessica Fye's trades and holding each position for 3 Months would result in 76.19% of your transactions generating a profit, with an average return of +25.57% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

19/20 ratings generated profit

Average Return

+89.63%

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +89.63% per trade.

2 Years

Joseph SchwartzLeerink Partners

Success Rate

19/20 ratings generated profit

Average Return

+194.73%

Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +194.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSM has received 55 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 201.06.

Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$0.38 with a range of -$0.75 to $0.04. The previous quarter’s EPS was -$0.06. INSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.10% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $501.46M with a range of $457.00M to $524.08M. The previous quarter’s sales results were $425.49M. INSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 57.92% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 201.06.

What is INSM’s upside potential, based on the analysts’ average price target?

Insmed has 88.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSM a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.

What is Insmed’s price target?

The average price target for Insmed is 201.06. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $243.00 ,the lowest forecast is $169.00. The average price target represents 88.04% Increase from the current price of $106.92.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of INSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Insmed (INSM) Stock Forecast & Price Target

INSM Analyst Ratings

INSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

INSM Analyst Recommendation Trends

INSM Financial Forecast

INSM Earnings Forecast

INSM Sales Forecast

INSM Stock Forecast FAQ

Detailed List of Analyst Forecasts